535 Bourke Street
Level 22
Melbourne, VIC 3000
Australia
61 3 9660 4900
https://www.clinuvel.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Philippe Jacques Wolgen M.B.A., M.D. | CEO, MD & Director | 2.78M | N/A | 1963 |
Mr. Darren Michael Keamy B.Com., CPA | CFO & Company Secretary | 415.08k | N/A | 1973 |
Dr. Dennis J. Wright | Chief Scientific Officer | 340.5k | N/A | N/A |
Mr. Lachlan Hay | Director of Global Operations | N/A | N/A | N/A |
Mr. Malcolm Bull | Head of Australian Operations & Investor Relations | N/A | N/A | N/A |
Dr. Rose Quadbeck-Diel | Senior Vice President of Regulatory Affairs | N/A | N/A | N/A |
Dr. Azza Hamila | Head of Quality & Drug Safety | N/A | N/A | N/A |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Clinuvel Pharmaceuticals Limited’s ISS governance QualityScore as of 29 April 2024 is 6. The pillar scores are Audit: 8; Board: 5; Shareholder rights: 5; Compensation: 9.